Loading company…
Yongsheng Buluo develops immune cell and stem cell therapies, including a CAR-NK platform for solid tumors.
Yongsheng Buluo researches immune cell and stem cell drugs, including a universal CAR-NK cell platform targeting solid tumors. Its work also includes gene-edited cell therapies, tumor mRNA vaccines and organ regeneration. Founded in 2024 in Huangshan, China, it raised angel funding in April 2025 co-led by JHF Investment and Prosperity Investment to build a stem cell laboratory and advance CAR-NK treatment technology.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in